Jade-1: its structure, regulation and functions in the renal cancer.

Author(s): Y.-C. Zhang, W.-Q. Du, R.-Y. Zhang, J.-N. Zheng, D.-S. Pei.

Journal Name: Current Molecular Medicine

Volume 16 , Issue 1 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


Jade-1 is originally identified by the yeast two-hybrid system as a protein partner of von Hippel-Lindau (pVHL) tumor suppressor, a well-known renal tumor suppressor. In cellular signaling pathways, many upstream Jade-1 regulators, such as pVHL, CK1α, PC1, and NPHP4, can control its activity by stabilization, phosphorylation, and nuclear translocation. Numerous downstream effectors, including β-catenin, AKT, p21, and Bcl-2, are well modulated by Jade-1, which mainly regulates cell proliferation and apoptosis. Jade-1 is also deemed to be a candidate of transcriptional co-activator associated with histone acetyltransferase (HAT) activity. This review focuses on the anticancer role of Jade-1 in clear cell renal carcinoma and the inhibitory effect of Jade-1 on cystic renal diseases. This review aims to provide a basis of disease prevention or therapy.

Keywords: Jade-1, pVHL, renal cancer, renal cyst, HAT, β-catenin.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [63 - 69]
Pages: 7
DOI: 10.2174/1566524016666151222144511
Price: $65

Article Metrics

PDF: 20
PRC: 1